Hemophagocytic Lymphohistiocytosis (HLH) in Malaria-Negative Febrile Adult
In a malaria-negative adult with fever, cytopenias, and markedly elevated ferritin suspicious for HLH, immediately initiate diagnostic workup using HLH-2004 criteria while simultaneously starting high-dose corticosteroids (dexamethasone 10 mg/m² or methylprednisolone 1 g/day for 3-5 days) if 5 of 8 criteria are met or clinical suspicion is high, and aggressively search for the underlying trigger—infection, malignancy, or autoimmune disease—as this determines definitive management. 1
Diagnostic Workup
Immediate Laboratory Assessment
Apply the HLH-2004 criteria (need 5 of 8) 1:
- Fever (often present)
- Cytopenias affecting ≥2 lineages: Hemoglobin <90 g/L, platelets <100×10⁹/L, neutrophils <1.0×10⁹/L
- Ferritin ≥500 μg/L (but >7,000-10,000 μg/L is highly suggestive in adults; >10,000 μg/L raises specificity to ~90% though less than in pediatrics) 1
- Hypertriglyceridemia (≥3.0 mmol/L) and/or hypofibrinogenemia (≤1.5 g/L)
- Splenomegaly (clinical or imaging)
- Hemophagocytosis in bone marrow, spleen, or lymph nodes (absence does not exclude HLH)
- Low/absent NK cell activity (if available)
- Elevated soluble CD25 (sCD25) ≥2,400 U/mL
Critical point: Hyperferritinemia >10,000 μg/L should immediately trigger HLH evaluation, though this threshold is less specific in adults than children 1. The HScore ≥169 provides 82-95% sensitivity and 60-94% specificity for adult HLH 2, 3.
Mandatory Trigger Search (Must Continue Despite Treatment)
Infections (most common in adults, 42.5% of ICU cases) 1, 4:
- EBV serology and DNA PCR (>10³ copies/mL significant) 1
- HIV, CMV, influenza testing
- Blood cultures (repeat if initially negative)
- Consider Leishmania, rickettsial disease, tuberculosis based on exposure
Malignancies (40-70% of adult HLH, particularly with age) 1:
- Lymphomas are the dominant cause: T-cell/NK-cell (35%), B-cell (32%), Hodgkin (6%)
- PET-CT imaging to detect occult lymphoma 1, 5
- Bone marrow biopsy (essential—may reveal hemophagocytosis AND underlying malignancy) 1, 5
- Elevated sCD25/ferritin ratio suggests lymphoma-associated HLH 1
- Consider splenectomy if splenomegaly with unknown cause (lymphoma may hide in spleen) 1
Autoimmune triggers (if history of Still's disease, lupus, vasculitis) 1
Genetic Testing
Consider in young adults, family history of consanguinity/HLH, recurrent disease, or unknown trigger—but do not delay treatment pending results 1. Hypomorphic mutations (e.g., PRF1 A91V) found in 7-25% of adults but present in 10% of healthy individuals 1.
Acute Management Algorithm
Step 1: ICU Admission and Supportive Care
- ICU admission is appropriate given multiorgan dysfunction risk and mortality of 20-88% (60% in ICU cohorts, 71% in malignancy-associated HLH) 1, 4
- Broad-spectrum antibiotics are essential—secondary infections are a major cause of death 1
- Fluid resuscitation per standard sepsis protocols (HLH often mimics sepsis; both can coexist) 1
- Antimicrobial prophylaxis: Pneumocystis jirovecii, fungal, and antiviral prophylaxis due to severe T-cell depletion from disease and treatment 1
Step 2: Immediate HLH-Specific Therapy
For severe HLH with organ failure or rapid deterioration 1:
- Dexamethasone 10 mg/m² daily OR methylprednisolone 1 g/day for 3-5 days (pulse dosing) 1
- Etoposide 150 mg/m² (reduce to 50-100 mg/m² in elderly/comorbid patients; reduce dose in renal impairment, NOT for isolated liver dysfunction) 1
- IVIG 1.6 g/kg over 2-3 days (anti-inflammatory effects) 1
For less severe or improving disease 1:
- Short course of corticosteroids alone (with/without IVIG)
- Weekly reevaluation for need to escalate to etoposide 1
For MAS-HLH (autoimmune background) 1, 6:
- High-dose methylprednisolone (1 g/day × 3-5 days) first-line
- Add cyclosporine A (2-7 mg/kg/day) if insufficient response
- Anakinra (IL-1 blockade): 2-10 mg/kg/day subcutaneously in divided doses 1
- Consider tocilizumab (IL-6 blockade) 1
Step 3: Trigger-Specific Modifications
EBV-HLH 1:
- Add rituximab 375 mg/m² weekly × 2-4 doses (targets B-cell EBV reservoir)
- Monitor EBV DNA, ferritin, sCD25 to guide rituximab duration
- Note: Rituximab does NOT replace corticosteroids/etoposide (EBV also infects T/NK cells)
Malignancy-associated HLH 1, 5:
- Treat the underlying malignancy (e.g., R-CHOP for lymphoma)—this is definitive therapy
- Corticosteroids/anakinra provide temporary control only
- Etoposide use is controversial; prioritize cancer-directed therapy
Infection-associated HLH (Leishmania, rickettsial, TB) 1:
- Pathogen-specific antimicrobials are primary treatment
- Avoid HLH-94 immunosuppression in these cases (responds to antimicrobials alone)
HIV-HLH 1:
- Initiate highly active antiretroviral therapy
- Short course corticosteroids ± IVIG
- Etoposide used in ~50% of cases
Step 4: Monitoring and Duration
- Weekly reassessment of need for continued etoposide (many require 8 weeks) 1
- Monitor ferritin (failure to decrease predicts mortality; minimum >4,083 μg/L post-diagnosis predicts 30-day mortality with 94% sensitivity) 4
- Track sCD25, cell counts, triglycerides, fibrinogen
- Ferritin >10,000 μg/L after treatment initiation is highly predictive of poor outcome 4
Critical Pitfalls to Avoid
Delaying treatment while awaiting bone marrow biopsy—start therapy if clinical suspicion is high even without meeting all 5 criteria 1
Assuming hyperferritinemia >10,000 μg/L is 90% specific in adults—this is pediatric data; adult specificity is lower, requiring integration of other criteria 1, 2
Using immunosuppression for pathogen-specific HLH (Leishmania, rickettsial, TB)—these respond to antimicrobials alone 1
Stopping trigger search after starting treatment—continue investigating for occult malignancy throughout treatment course 1
Treating malignancy-associated HLH with immunosuppression alone—definitive treatment requires addressing the underlying cancer 1, 5
Overlooking secondary infections—these cause major mortality; maintain broad antimicrobial prophylaxis 1
Confusing "HLH during chemotherapy" with malignancy-triggered HLH—the former is usually infection-induced and requires different management (corticosteroids ± IVIG, spare etoposide to allow marrow recovery) 1